Enovis Corporation (NYSE:ENOV) Given Average Recommendation of “Buy” by Brokerages

Enovis Corporation (NYSE:ENOV) has earned an average rating of “Buy” from the six brokerages that are covering the stock, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have issued a report on the stock in the last year is $51.00.

A number of research firms have recently commented on ENOV. Needham & Company LLC reduced their price objective on shares of Enovis from $57.00 to $49.00 and set a “buy” rating for the company in a report on Thursday, August 7th. JMP Securities reduced their price objective on shares of Enovis from $62.00 to $55.00 and set a “market outperform” rating for the company in a report on Friday, May 9th. UBS Group reduced their price objective on shares of Enovis from $65.00 to $57.00 and set a “buy” rating for the company in a report on Friday, August 8th. Evercore ISI reduced their price objective on shares of Enovis from $48.00 to $46.00 and set an “outperform” rating for the company in a report on Tuesday, July 8th. Finally, Canaccord Genuity Group reduced their price objective on shares of Enovis from $70.00 to $58.00 and set a “buy” rating for the company in a report on Friday, August 8th.

Insider Activity

In other Enovis news, CFO Phillip Benjamin (Ben) Berry purchased 2,500 shares of the stock in a transaction dated Wednesday, August 20th. The stock was bought at an average price of $29.71 per share, for a total transaction of $74,275.00. Following the transaction, the chief financial officer directly owned 116,729 shares in the company, valued at $3,468,018.59. This represents a 2.19% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Bradley J. Tandy acquired 3,200 shares of Enovis stock in a transaction that occurred on Friday, August 22nd. The shares were purchased at an average cost of $31.41 per share, for a total transaction of $100,512.00. Following the purchase, the senior vice president directly owned 43,515 shares in the company, valued at $1,366,806.15. The trade was a 7.94% increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 2.70% of the company’s stock.

Institutional Trading of Enovis

A number of institutional investors have recently made changes to their positions in ENOV. California State Teachers Retirement System increased its position in Enovis by 0.7% during the fourth quarter. California State Teachers Retirement System now owns 52,236 shares of the company’s stock worth $2,292,000 after acquiring an additional 350 shares during the period. Humankind Investments LLC increased its position in Enovis by 8.6% during the first quarter. Humankind Investments LLC now owns 5,688 shares of the company’s stock worth $217,000 after acquiring an additional 452 shares during the period. US Bancorp DE increased its position in Enovis by 2.5% during the first quarter. US Bancorp DE now owns 19,031 shares of the company’s stock worth $727,000 after acquiring an additional 462 shares during the period. Leisure Capital Management increased its position in Enovis by 2.2% during the first quarter. Leisure Capital Management now owns 22,903 shares of the company’s stock worth $875,000 after acquiring an additional 489 shares during the period. Finally, Teacher Retirement System of Texas increased its position in Enovis by 6.1% during the second quarter. Teacher Retirement System of Texas now owns 8,664 shares of the company’s stock worth $272,000 after acquiring an additional 495 shares during the period. Institutional investors own 98.45% of the company’s stock.

Enovis Stock Performance

Shares of ENOV opened at $30.88 on Tuesday. The company’s fifty day moving average is $30.08 and its 200-day moving average is $33.39. Enovis has a 12 month low of $25.47 and a 12 month high of $49.83. The firm has a market cap of $1.77 billion, a price-to-earnings ratio of -2.17 and a beta of 1.68. The company has a quick ratio of 1.15, a current ratio of 2.25 and a debt-to-equity ratio of 0.53.

Enovis (NYSE:ENOV) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.79 EPS for the quarter, topping the consensus estimate of $0.74 by $0.05. The company had revenue of $564.50 million for the quarter, compared to analyst estimates of $555.80 million. Enovis had a negative net margin of 37.80% and a positive return on equity of 6.78%. Enovis’s quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.62 EPS. Enovis has set its FY 2025 guidance at 3.050-3.200 EPS. Equities analysts expect that Enovis will post 2.79 EPS for the current fiscal year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.